Damage to vascular endothelial cells by high insulin levels is associated with increased expression of ChemR23, and attenuated by PPAR-gamma agonist, rosiglitazone

被引:0
|
作者
Hao, Fei [1 ]
Mu, Jia-wei [1 ]
Zhang, Hui-juan [1 ]
Kuang, Hong-yu [1 ]
Yu, Qiu-xia [1 ]
Bai, Meng-meng [1 ]
Meng, Ping [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 1, Dept Endocrinol, Harbin 150001, Peoples R China
基金
中国国家自然科学基金;
关键词
hyperinsulinemia; ChemR23; PPAR gamma; vascular endothelial cells; OXIDATIVE STRESS; CHEMERIN LEVELS; RESISTANCE; PROLIFERATION; DYSFUNCTION; ADIPOCYTE; OBESITY; HYPERINSULINEMIA; ADIPONECTIN; ACTIVATION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: This study investigated the effect of different insulin concentrations on the activity of vascular endothelial cells (VECs), and the role of PPAR. activator rosiglitazone (RGZ) on the expression of the chemerin receptor, ChemR23, in insulin-treated human umbilical vein endothelial cells (HUVECs). METHODS: Cell viability was determined in HUVECs treated with different insulin concentrations. Immunofluorescence staining was used to detect ChemR23 expression in insulin-treated HUVECs. Western blot assays were used to evaluate ChemR23 and PPAR gamma protein expression in insulin-treated HUVECs after pretreatment with PPAR gamma activator (RGZ) or inhibitor (GW9662). RESULTS: High insulin concentrations significantly inhibited HUVEC cell viability compared to low insulin concentrations, and this inhibition was attenuated by pretreatment with RGZ. High concentrations of insulin caused a significant upregulation of ChemR23 and a significant downregulation of PPAR gamma. These effects were attenuated by RGZ pretreatment, while PPAR gamma antagonist, GW9662 reversed this attenuation. CONCLUSION: ChemR23 upregulation may play a role in VEC damage caused by high concentrations of insulin. The protective effect of PPAR gamma activation in VECs may be mediated via ChemR23 downregulation.
引用
收藏
页码:59 / 66
页数:8
相关论文
共 5 条
  • [1] Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells
    Desouza, Cyrus V.
    Gerety, Moira
    Hamel, Frederick G.
    VASCULAR PHARMACOLOGY, 2009, 51 (2-3) : 162 - 168
  • [2] PPAR-gamma agonist rosiglitazone restores impaired in vivo reendothelialization capacity of endothelial progenitor cells in patients with diabetes: critical role of NAD(P)H oxidase and NO availability
    Sorrentino, S.
    Bahlmann, F.
    Besler, C.
    Mueller, M.
    Fliser, D.
    Haller, H.
    Drexler, H.
    Landmesser, U.
    EUROPEAN HEART JOURNAL, 2006, 27 : 132 - 132
  • [3] Telomerase reverse transcriptase mediates anti-senescence and endothelial-protective effects of the ppar-gamma agonist pioglitazone in the vascular wall and circulating mononuclear cells in mice
    Werner, C. M.
    Gensch, C.
    Poess, J.
    Boehm, M.
    Laufs, U.
    EUROPEAN HEART JOURNAL, 2010, 31 : 832 - 832
  • [4] High Levels of Vascular Endothelial Growth Factor Protein Expression Are Associated With an Increased Risk of Transfusion Dependence in Myelodysplastic Syndromes
    Gianelli, Umberto
    Fracchiolla, Nicola S.
    Bucciarelli, Paolo
    Ferla, Valeria
    Boiocchi, Leonardo
    Savi, Federica
    Moro, Alessia
    Reda, Gianluigi
    Bosari, Silvano
    Cortelezzi, Agostino
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2013, 139 (03) : 380 - 387
  • [5] Periodontal inflammation is associated with increased circulating levels of endothelial progenitor cells: a retrospective cohort study in a high vascular risk population
    Vazquez-Reza, Maria
    Custodia, Antia
    Lopez-Dequidt, Iria
    Aramburu-Nunez, Marta
    Romaus-Sanjurjo, Daniel
    Ouro, Alberto
    Botelho, Joao
    Machado, Vanessa
    Iglesias-Rey, Ramon
    Pias-Peleteiro, Juan Manuel
    Leira, Rogelio
    Blanco, Juan
    Castillo, Jose
    Sobrino, Tomas
    Leira, Yago
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2023, 14